Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Profit After Tax (2020 - 2026)

Rani Therapeutics Holdings' Profit After Tax history spans 7 years, with the latest figure at -$8.0 million for Q1 2026.

  • On a quarterly basis, Profit After Tax fell 10.34% to -$8.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$46.2 million, a 7.19% decrease, with the full-year FY2025 number at -$40.9 million, up 27.63% from a year prior.
  • Profit After Tax came in at -$8.0 million for Q1 2026, up from -$21.6 million in the prior quarter.
  • The five-year high for Profit After Tax was -$5.4 million in Q3 2025, with the low at -$21.6 million in Q4 2025.
  • Historically, Profit After Tax has averaged -$12.9 million across 5 years, with a median of -$13.8 million in 2022.
  • Biggest five-year swings in Profit After Tax: plummeted 191.08% in 2022 and later soared 59.07% in 2023.
  • Year by year, Profit After Tax stood at -$17.3 million in 2022, then surged by 59.07% to -$7.1 million in 2023, then plummeted by 121.5% to -$15.7 million in 2024, then crashed by 37.27% to -$21.6 million in 2025, then surged by 62.86% to -$8.0 million in 2026.
  • Business Quant data shows Profit After Tax for RANI at -$8.0 million in Q1 2026, -$21.6 million in Q4 2025, and -$5.4 million in Q3 2025.